Quick Answer
Inhibrx Biosciences, Inc. reported Total Revenue of $1.30 million for fiscal year 2025.
Inhibrx Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $1.30M +550.0% |
$200.0K -88.9% |
$1.80M | — |
| Net Income | -$140.06M -108.3% |
$1.69B +799.2% |
-$241.36M | — |
| Diluted EPS | -$9.04 -108.0% |
$112.62 +649.9% |
-$20.48 | — |
| Total Assets | $146.48M -19.0% |
$180.77M -41.3% |
$307.89M | — |
| Cash and Equivalents | $124.22M -18.6% |
$152.60M -45.1% |
$277.92M | — |
| Long-Term Debt | $100.56M | $0.00 -100.0% |
$206.97M | — |
| Stockholders Equity | $7.99M -94.0% |
$133.58M +207.1% |
$43.50M -25.1% |
$58.06M |
| R&D Expense | $113.03M -44.5% |
$203.74M +6.3% |
$191.64M | — |
| Operating Income | -$135.03M +59.3% |
-$331.45M -51.2% |
-$219.22M | — |
| Shares Outstanding | 14.58M +0.7% |
14.48M -69.4% |
47.37M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | -100.0% |
| Net Income | September 30, 2025 | -$35.26M | +19.6% | -23.0% |
| Diluted EPS | September 30, 2025 | -$2.28 | +19.7% | -23.2% |
| Total Assets | September 30, 2025 | $177.47M | -20.3% | -16.3% |
| Cash and Equivalents | September 30, 2025 | $153.09M | -22.0% | -17.9% |
| Long-Term Debt | September 30, 2025 | $99.92M | — | +0.6% |
| Stockholders Equity | September 30, 2025 | $36.83M | -79.4% | -46.3% |
| R&D Expense | September 30, 2025 | $28.54M | -26.6% | +28.1% |
| Operating Income | September 30, 2025 | -$33.81M | +27.7% | -23.5% |
| Shares Outstanding | September 30, 2025 | 14.50M | +0.2% | +0.2% |
- Inhibrx Biosciences, Inc. reported Total Revenue of $1.30 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed an increase of +550.0% in Total Revenue compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Net Income of -$140.06 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -108.3% in Net Income compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Diluted EPS of $9.04 per share (loss) for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -108.0% in Diluted EPS compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Total Assets of $146.48 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -19.0% in Total Assets compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Cash and Equivalents of $124.22 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -18.6% in Cash and Equivalents compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Long-Term Debt of $100.56 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. reported Stockholders Equity of $7.99 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -94.0% in Stockholders Equity compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported R&D Expense of $113.03 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed a decrease of -44.5% in R&D Expense compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Operating Income of -$135.03 million for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed an increase of +59.3% in Operating Income compared to the prior fiscal year.
- Inhibrx Biosciences, Inc. reported Shares Outstanding of 14.58 million shares for fiscal year 2025.
- Inhibrx Biosciences, Inc. showed an increase of +0.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: